ISSN 1673-3770 CN 37-1437/R
Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2023, Vol. 37 ›› Issue (5): 198-205.doi: 10.6040/j.issn.1673-3770.0.2022.279
• Review • Previous Articles
HUANG Yanli1,2, LI Junzheng1,3
CLC Number:
| [1] Denoyer D, Clatworthy SAS, Cater MA. Copper complexes in cancer therapy[J]. Met Ions Life Sci, 2018,5:18:/books/9783110470734/9783110470734-022/9783110470734-022.xml. doi: 10.1515/9783110470734-022 [2] Jiang Y, Huo Z, Qi X, et al. Copper-induced tumor cell death mechanisms and antitumor theragnostic applications of copper complexes[J]. Nanomedicine(Lond), 2022, 17(5): 303-324. doi:10.2217/nnm-2021-0374 [3] Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins[J]. Science, 2022, 375(6586): 1254-1261. doi:10.1126/science.abf0529 [4] 朱洁洁, 王华. 铜诱导调节性细胞死亡的作用机制与抗肿瘤治疗的研究进展[J]. 江苏大学学报(医学版), 2022, 32(4): 326-331, 349. doi:10.13312/j.issn.1671-7783.y220122 ZHU Jiejie, WANG Hua. Mechanism of copper-induced regulatory cell death and research progress of anti-tumor therapy[J] Journal of Jiangsu University(Medicine Edition), 2022, 32(4): 326-331, 349. doi:10.13312/j.issn.1671-7783.y220122 [5] Lossow K, Schwarz M, Kipp AP. Are trace element concentrations suitable biomarkers for the diagnosis of cancer? [J]. Redox Biol, 2021, 42: 101900. doi:10.1016/j.redox.2021.101900 [6] Wang WJ, Wang X, Luo JJ, et al. Serum copper level and the copper-to-zinc ratio could be useful in the prediction of lung cancer and its prognosis: a case-control study in northeast China[J]. Nutr Cancer, 2021, 73(10): 1908-1915. doi:10.1080/01635581.2020.1817957 [7] Denoyer D, Masaldan S, la Fontaine S, et al. Targeting copper in cancer therapy: ‘Copper That Cancer’[J]. Metallomics, 2015, 7(11): 1459-1476. doi:10.1039/c5mt00149h [8] Nagai M, Vo NH, Shin Ogawa L, et al. The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells[J]. Free Radic Biol Med, 2012, 52(10): 2142-2150. doi:10.1016/j.freeradbiomed.2012.03.017 [9] da Silva DA, De Luca A, Squitti R, et al. Copper in tumors and the use of copper-based compounds in cancer treatment[J]. J Inorg Biochem, 2022, 226: 111634. doi:10.1016/j.jinorgbio.2021.111634 [10] 张转, 刘涛, 白治丽, 等. 氧化应激与噪音性聋发病机制及治疗进展[J]. 山东大学耳鼻喉眼学报, 2017, 31(5): 101-103, 106. doi: 10.6040/j.issn.1673-3770.0.2017.185 ZHANG Zhuan, LIU Tao, BAI Zhili, et al. Evolution of oxidative stress in the pathogenesis and treatment of noise-induced hearing loss[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2017, 31(5): 101-103, 106. doi: 10.6040/j.issn.1673-3770.0.2017.185 [11] Jomova K, Hudecova L, Lauro P, et al. The effect of Luteolin on DNA damage mediated by a copper catalyzed Fenton reaction[J]. J Inorg Biochem, 2022, 226: 111635. doi:10.1016/j.jinorgbio.2021.111635 [12] Ngamchuea K, Batchelor-McAuley C, Compton RG. The copper(II)-catalyzed oxidation of glutathione[J]. Chemistry, 2016, 22(44): 15937-15944. doi:10.1002/chem.201603366 [13] Kang Z, Qiao N, Liu G, et al. Copper-induced apoptosis and autophagy through oxidative stress-mediated mitochondrial dysfunction in male germ cells[J]. Toxicol In Vitro, 2019, 61: 104639. doi:10.1016/j.tiv.2019.104639 [14] Zhang Z, Wang H, Yan M, et al. Novel copper complexes as potential proteasome inhibitors for cancer treatment?(Review)[J]. Mol Med Rep, 2017, 15(1): 3-11. doi:10.3892/mmr.2016.6022 [15] Zhou T, Cai Y, Liang L, et al. Discovery of a potent and highly specific β2 proteasome inhibitor from a library of copper complexes[J]. Bioorg Med Chem Lett, 2016, 26(23): 5780-5784. doi:10.1016/j.bmcl.2016.10.043 [16] Han J, Liu L, Yue X, et al. A binuclear complex constituted by diethyldithiocarbamate and copper(I)functions as a proteasome activity inhibitor in pancreatic cancer cultures and xenografts[J]. Toxicol Appl Pharmacol, 2013, 273(3): 477-483. doi:10.1016/j.taap.2013.09.009 [17] Fricker LD. Proteasome inhibitor drugs[J]. Annu Rev Pharmacol Toxicol, 2020, 60: 457-476. doi:10.1146/annurev-pharmtox-010919-023603 [18] Oliveri V, Lanza V, Milardi D, et al. Amino- and chloro-8-hydroxyquinolines and their copper complexes as proteasome inhibitors and antiproliferative agents[J]. Metallomics, 2017, 9(10): 1439-1446. doi:10.1039/c7mt00156h [19] Yi M, Jiao D, Qin S, et al. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment[J]. Mol Cancer, 2019, 18(1): 60. doi:10.1186/s12943-019-0974-6 [20] Baldari S, Di Rocco G, Toietta G. Current biomedical use of copper chelation therapy[J]. Int J Mol Sci, 2020, 21(3): E1069. doi:10.3390/ijms21031069 [21] Czonkowska A, Litwin T, Dusek P, et al. Wilson disease[J]. Nat Rev Dis Primers, 2018, 4(1): 21. doi:10.1038/s41572-018-0018-3 [22] Brewer GJ. Copper-lowering therapy with tetrathiomolybdate for cancer and diseases of fibrosis and inflammation[J]. J Trace Elem Exp Med, 2003, 16(4): 191-199. doi:10.1002/jtra.10045 [23] Chan N, Willis A, Kornhauser N, et al. Influencing the tumor microenvironment: a phase II study of copper depletion using tetrathiomolybdate in patients with breast cancer at high risk for recurrence and in preclinical models of lung metastases[J]. Clin Cancer Res, 2017, 23(3): 666-676. doi:10.1158/1078-0432.CCR-16-1326 [24] Morisawa A, Okui T, Shimo T, et al. Ammonium tetrathiomolybdate enhances the antitumor effects of cetuximab via the suppression of osteoclastogenesis in head and neck squamous carcinoma[J]. Int J Oncol, 2018, 52(3): 989-999. doi:10.3892/ijo.2018.4242 [25] Ryumon S, Okui T, Kunisada Y, et al. Ammonium tetrathiomolybdate enhances the antitumor effect of cisplatin via the suppression of ATPase copper transporting beta in head and neck squamous cell carcinoma[J]. Oncol Rep, 2019, 42(6): 2611-2621. doi:10.3892/or.2019.7367 [26] Yi M, Jiao D, Qin S, et al. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment[J]. Mol Cancer, 2019, 18(1): 60. doi:10.1186/s12943-019-0974-6 [27] Zhou P, Qin J, Zhou C, et al. Multifunctional nanoparticles based on a polymeric copper Chelator for combination treatment of metastatic breast cancer[J]. Biomaterials, 2019, 195: 86-99. doi:10.1016/j.biomaterials.2019.01.007 [28] Tsvetkov P, Detappe A, Cai K, et al. Mitochondrial metabolism promotes adaptation to proteotoxic stress[J]. Nat Chem Biol, 2019, 15(7): 681-689. doi:10.1038/s41589-019-0291-9 [29] Cobine PA, Brady DC. Cuproptosis: Cellular and molecular mechanisms underlying copper-induced cell death[J]. Mol Cell, 2022, 82(10):1786-1787. doi:10.1016/j.molcel.2022.05.001 [30] Kahlson MA, Dixon SJ. Copper-induced cell death[J]. Science, 2022, 375(6586): 1231-1232. doi:10.1126/science.abo3959 [31] Tang D, Chen X, Kroemer G. Cuproptosis: a copper-triggered modality of mitochondrial cell death[J]. Cell Res, 2022, 32(5): 417-418. doi:10.1038/s41422-022-00653-7 [32] 林锦贤, 王攀, 吴欣谋, 等. 铜稳态失调诱导调节性细胞死亡及其调控的研究进展[J]. 江苏大学学报(医学版), 2022, 32(4): 306-317. doi:10.13312/j.issn.1671-7783.y220089 LIN Jinxian, WANG Pan, WU Xinmou, et al. Research progress of regulatory cell death induced by copper homeostasis disorder and its regulation[J]. Journal of Jiangsu University(Medicine Edition), 2022, 32(4): 306-317. doi:10.13312/j.issn.1671-7783.y220089 [33] Cappuccino JG, Banks S, Brown G, et al. The effect of copper and other metal ions on the antitumor activity of pyruvaldehyde bis(thiosemicarbazone)[J]. Cancer Res, 1967, 27(5): 968-973 [34] Singh P, Youden B, Yang YK, et al. Synergistic multimodal cancer therapy using glucose Oxidase@CuS nanocomposites[J]. ACS Appl Mater Interfaces, 2021, 13(35): 41464-41472. doi:10.1021/acsami.1c12235 [35] Michalczyk K, Cymbaluk-Poska A. The role of zinc and copper in gynecological malignancies[J]. Nutrients, 2020,12(12):3732. doi: 10.3390/nu12123732 [36] Blockhuys S, Celauro E, Hildesjö C, et al. Defining the human copper proteome and analysis of its expression variation in cancers[J]. Metallomics, 2017, 9(2): 112-123. doi:10.1039/c6mt00202a [37] Cui L, Gouw AM, LaGory EL, et al. Mitochondrial copper depletion suppresses triple-negative breast cancer in mice[J]. Nat Biotechnol, 2021, 39(3): 357-367. doi:10.1038/s41587-020-0707-9 [38] Zeng XB, Liu CX, Yao J, et al. Breast cancer stem cells, heterogeneity, targeting therapies and therapeutic implications[J]. Pharmacol Res, 2021, 163: 105320. doi:10.1016/j.phrs.2020.105320 [39] Wang Y, Li W, Patel SS, et al. Blocking the formation of radiation-induced breast cancer stem cells[J]. Oncotarget, 2014, 5(11): 3743-3755. doi:10.18632/oncotarget.1992 [40] Nilsson G, Kannius-Janson M. Forkhead Box F1 promotes breast cancer cell migration by upregulating lysyl oxidase and suppressing Smad2/3 signaling[J]. BMC Cancer, 2016, 16: 142. doi:10.1186/s12885-016-2196-2 [41] Liu YL, Bager CL, Willumsen N, et al. Tetrathiomolybdate(TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer[J]. NPJ Breast Cancer, 2021, 7(1): 108. doi:10.1038/s41523-021-00313-w [42] Liao Y, Zhao J, Bulek K, et al. Inflammation mobilizes copper metabolism to promote colon tumorigenesis via an IL-17-STEAP4-XIAP axis[J]. Nat Commun, 2020, 11(1): 900. doi:10.1038/s41467-020-14698-y [43] Aubert L, Nandagopal N, Steinhart Z, et al. Copper bioavailability is a KRAS-specific vulnerability in colorectal cancer[J]. Nat Commun, 2020, 11(1): 3701. doi:10.1038/s41467-020-17549-y [44] Gao W, Huang Z, Duan J, et al. Elesclomol induces copper-dependent ferroptosis in colorectal cancer cells via degradation of ATP7A[J]. Mol Oncol, 2021, 15(12): 3527-3544. doi:10.1002/1878-0261.13079 [45] Xiong K, Zhou Y, Karges J, et al. Autophagy-dependent apoptosis induced by apoferritin-Cu(II)nanoparticles in multidrug-resistant colon cancer cells[J]. ACS Appl Mater Interfaces, 2021, 13(33): 38959-38968. doi:10.1021/acsami.1c07223 [46] Hu YT, Qian YC, Wei JS, et al. The disulfiram/copper complex induces autophagic cell death in colorectal cancer by targeting ULK1[J]. Front Pharmacol, 2021, 12: 752825. doi:10.3389/fphar.2021.752825 [47] Huang X, Hou Y, Weng X, et al. Diethyldithiocarbamate-copper complex(CuET)inhibits colorectal cancer progression via miR-16-5p and 15b-5p/ALDH1A3/PKM2 axis-mediated aerobic glycolysis pathway[J]. Oncogenesis, 2021, 10(1): 4. doi:10.1038/s41389-020-00295-7 [48] Wang WJ, Wang X, Luo JJ, et al. Serum copper level and the copper-to-zinc ratio could be useful in the prediction of lung cancer and its prognosis: a case-control study in northeast China[J]. Nutr Cancer, 2021, 73(10): 1908-1915. doi:10.1080/01635581.2020.1817957 [49] Falls-Hubert KC, Butler AL, Gui K, et al. Disulfiram causes selective hypoxic cancer cell toxicity and radio-chemo-sensitization via redox cycling of copper[J]. Free Radic Biol Med, 2020, 150: 1-11. doi:10.1016/j.freeradbiomed.2020.01.186 [50] Tsang T, Posimo JM, Gudiel AA, et al. Copper is an essential regulator of the autophagic kinases ULK1/2 to drive lung adenocarcinoma[J]. Nat Cell Biol, 2020, 22(4): 412-424. doi:10.1038/s41556-020-0481-4 [51] Kemp MG. Crosstalk between apoptosis and autophagy: environmental genotoxins, infection, and innate immunity[J]. J Cell Death, 2017,9: 1179670716685085. doi:10.1177/1179670716685085 [52] Wu X, Xue X, Wang LH, et al. Suppressing autophagy enhances disulfiram/copper-induced apoptosis in non-small cell lung cancer[J]. Eur J Pharmacol, 2018, 827: 1-12. doi:10.1016/j.ejphar.2018.02.039 [53] Cheng Q, Butler W, Zhou Y, et al. Pre-existing castration-resistant prostate cancer-like cells in primary prostate cancer promote resistance to hormonal therapy[J]. Eur Urol, 2022, 81(5): 446-455. doi:10.1016/j.eururo.2021.12.039 [54] Safi R, Nelson ER, Chitneni SK, et al. Copper signaling axis as a target for prostate cancer therapeutics[J]. Cancer?Res, 2014, 74(20): 5819-5831. doi:10.1158/0008-5472.CAN-13-3527 [55] Zhang T, Kephart J, Bronson E, et al. Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer[J]. Prostate, 2022, 82(7): 858-866. doi:10.1002/pros.24329 [56] Bakthavatsalam S, Sleeper ML, Dharani A, et al. Leveraging γ-glutamyl transferase to direct cytotoxicity of copper dithiocarbamates against prostate cancer cells[J]. Angew Chem Int Ed Engl, 2018, 57(39): 12780-12784. doi:10.1002/anie.201807582 [57] Machado JF, Sequeira D, Marques F, et al. New copper(I)complexes selective for prostate cancer cells[J]. Dalton?Trans, 2020, 49(35): 12273-12286. doi:10.1039/d0dt02157a [58] Voli F, Valli E, Lerra L, et al. Intratumoral copper modulates PD-L1 expression and influences tumor immune evasion[J]. Cancer Res, 2020, 80(19): 4129-4144. doi:10.1158/0008-5472.CAN-20-0471 |
| [1] | MA Jingyuan, WU Tianyi, SUN Zhanwei, WANG Weiwei, LI Shichao, WANG Guangke. Correlation between sinonasal inverted papilloma and peripheral inflammatory blood markers [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(4): 35-39. |
| [2] | The objective of this study was to analyze the effects and possible regulatory mechanisms that Notch receptors could have on cisplatin resistance, observed in nasopharyngeal carcinoma. MethodsWestern blot analysis was used for the detection of Notch receptor expression in nasopharyngeal carcinoma cells and cisplatin-resistant nasopharyngeal carcinoma cells(5-8F, 5-8F/CDDP). Flow cytometry was used to investigate how the combined treatment with 10 μM CDDP and different concentrations of γ-secretase inhibitor(DAPT)could affect apoptosis in 5-8F/CDDP cells. Flow cytometry was also used for the detection of cell cycle stages in DAPT-treated 5-8F / CDDP cells. Finally, western blotting was also used for the detection of drug resistance-related protein expression. All experiments were followed by statistical data analysis. ResultsWe observed significantly higher Notch1 and Notch4 receptor expression in 5-8F/CDDP cells than in 5-8F cells(P=0.003, P=0.004). Furthermore, we described that Notch signaling was inhibited by DAPT in 5-8F/CDDP cells, followed by a significant increase in the apoptosis rate and decrease in cell proliferation, induced by cisplatin in a dose-dependent manner(P<0.05). Moreover, after inhibiting the Notch signaling pathway in 5-8F/CDDP cells, DAPT treatment significantly decreased the expression of Cyclin E and CDK-2, proteins involved in cell cycle regulation, and contributed to blocking the cells in the G1/S phase(P<0.05). At the same time, the expression levels of both the EMT-related protein Slug and the DNA excision repair protein ERCC1 significantly decreased, while that of E-Cadherin was up-regulated. ConclusionUp-regulated expression of Notch1 and Notch4 receptors is associated with cisplatin resistance in nasopharyngeal carcinoma cells. The inactivation of the Notch signaling pathway might thus have the potential to enhance the efficiency of cisplatin chemotherapy in drug-resistant nasopharyngeal carcinoma cells by inhibiting EMT rather than blocking the G1/S cell cycle phase.. Cisplatin resistance in nasopharyngeal carcinoma cells is affected by Notch receptors through the regulation of epithelial-mesenchymal transition rather than cell cycle controlHAN Jibo, ZOU You, YANG Rui, TAO Zezhang Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, ChinaAbstract:Objective〓 [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(4): 105-110. |
| [3] | This study aimed to describe the clinical features of 74 patients with cleft palate cysts and fistulas and analyze the diagnosis and treatment methods. MethodsBetween January 2010 and September 2019, the clinical data of 74 patients with branchial cleft cysts and fistulas were retrospectively reviewed and analyzed with related literature in our department. ResultsOf the 74 patients, 50 patients were diagnosed with second branchial cleft anomalies, 13 patients had first branchial cleft lesions, 10 patients had third branchial cleft lesions, and one patient had a fourth branchial cleft lesion. All patients received surgical treatment. After the exclusion of 3 patients who were lost to follow-up, 67 patients were successfully treated, 3 patients reported relapse, and 1 had permanent facial paralysis. ConclusionsThe clinical manifestations of congenital cleft palate cysts and fistulas are diverse, and the differential diagnosis is complicated. It is essential to perform a detailed physical examination and preoperative evaluation to make an accurate diagnosis. The approach for management is individualized, and surgical rehabilitation is the preferred treatment.. Clinical analysis of 74 cases of branchial cleft cysts and fistulasWANG Yingying, ZHANG Liqing, ZHOU Han, DONG Shikun, CHEN Haibing, CHEN Xi, DONG Weida Department of Otorhinolaryngology, The First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, Jiangsu, ChinaAbstract:Objective〓 [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(4): 111-116. |
| [4] | ObjectiveThe aim of this study was to provide new perspectives and targets for the treatment of HNSCC by screening differentially expressed genes during cetuximab treatment of head and neck squamous cell carcinoma(HNSCC)using bioinformatics. MethodsThe chip dataset, GSE109756, was downloaded from the GEO database, and the online analysis tool, GEO2R, was used to screen differentially expressed genes in head and neck squamous cell carcinoma tissues treated with and without cetuximab. The DAVID 6.8 and STRING online software were used to analyze the function of the differentially expressed genes, their pathway enrichment, and their protein interactions. Cytoscape was used to visualize and analyze the protein interactions. The online analysis tool, X2K, was used to find the transcription factors, the kinases of differentially expressed genes, and their mutual regulatory relationship with the targeted genes. ResultsNinety-one differentially expressed genes, including 50 up-regulated and 41 down-regulated genes(P<0.05; | logFC | > 1), were found in head and neck squamous cell carcinoma tissues treated with and without cetuximab. The GO and KEGG pathway analyses suggested that these differentially expressed genes were mainly enriched with immunomodulation, extracellular matrix, and other processes. Through the construction of a protein-protein interaction network, we screened CD163, VSIG4, and 3 other core differentially expressed genes(P<0.05), which were up-regulated after cetuximab treatment. In addition, our analysis shows that transcription factors, including SUZ12, TP63, and ESR1, played a key role in cetuximab treatment(P<0.05)and MAPK14, CDK1, and MAPK1 were the most important kinases during the process(P<0.05). ConclusionCD163, VSIG4, and the aforementioned transcription factors and protein kinases may be involved in the biological processes that underlie cetuximab treatment of HNSCC. This study provides new perspectives to facilitate further understanding of the biological mechanism that underlies cetuximab treatment of HNSCC and the exploration of the effectiveness of HNSCC treatment.. Analysis of differentially expressed genes during cetuximab treatment of head and neck squamous cell carcinoma using bioinformaticsYU Kena1, SUN Kaiyue2, ZHANG Jie1, JIN Peng1 1. Department of Otorhinolaryngology & Head and Neck Surgery, The Second Hospital of Shandong University, Jinan 250033, Shandong, China; 2. Shandong Provincial Otorhinolaryngology Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250022, Shandong, ChinaAbstract: [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(4): 117-124. |
| [5] | Zhili WANG,Zhe CHEN,Fangyu LIN,Yongchuan CHAI,Zhaoyan WANG. Facial nerve reconstruction in the parotid area under a variety of circumstances [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(1): 15-19. |
| [6] | Jian FENG,Han ZHOU,Shenghua SONG,Qing ZHAO,Jiacheng ZHANG,Yaqin LIU,Yujie SHEN,Weida DONG. Clinical analysis of 15 cases of adenoid cystic carcinoma in the paranasal sinuses and nasal cavity [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(5): 87-91. |
| [7] | Lin LI,Heng ZHANG,Yufei XIAN,Xiaoli SHENG. Expression and biological function of long chain non-coding cytoskeleton regulator RNA in nasopharyngeal carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(5): 69-72. |
| [8] | PAN Xiaofei, WANG Jun, XIAO Yang, MA Lijing. Effects of lncRNA CTB-147C22.8 and mRNA KLK6 on the invasion of recurrent respiratory papilloma cells [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(4): 66-70. |
| [9] | LUO Tongyong, YANG Huaqing, YUE Shengqing, JIA Quanfan, YUAN Long. Panitan single resistance and taxol as the first-line treatment of recurrent or metastatic head and neck cancer: a phase Ⅱ study [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(4): 71-75. |
| [10] | DING Jie, SUN Yan. Survey of overall sleep quality in 142 patients with laryngectomy [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(4): 76-81. |
| [11] | HUANG He, OUYANG Hui. Risk factors and prognosis of esophageal cancer with hypopharyngeal carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(4): 82-86. |
| [12] | ZHANG Xiaoping, YANG Dengquan, WANG Shaoxin, HUANG Xiaoming. Effects of continuous out-of-hospital administration on the quality of life in patients with laryngeal cancer [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(4): 169-174. |
| [13] | Ming LIU. Transoral laser microsurgery for early glottic neoplasms [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(4): 6-9. |
| [14] | Xiaohan SUN,Na LI. Application of laryngeal retention strategy in the treatment of laryngeal cancer - introduction to the clinical practice guide of the American Society of Clinical Oncology (2017) [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(4): 40-42. |
| [15] | Zelei HUANG,Qi SONG,Xiuying LU,Lanzhen CUI,Xiaoming LI. Effects of dihydroartemisinin on endoreticulum stress pathway in FaDu hypopharyngeal carcinoma cells [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(4): 31-35. |
|
||